Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04438083 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
A Phase 1 study, sponsored by CRISPR Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04438083: Clinical Trial Phase 1 study, sponsored by CRISPR Therapeutics.
NCT04438083 is a Phase 1 study that was terminated before completion, run by CRISPR Therapeutics. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04438083, a Phase 1 study, was terminated before completion, sponsored by CRISPR Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.
Primary Outcome
Adverse events defined as dose-limiting toxicities
Interventions
- BIOLOGICAL CTX130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 1 |
Why NCT04438083 stopped before completion
NCT04438083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which CTX130 is the first listed.
NCT04438083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04438083 about?
NCT04438083 is a clinical study titled "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)". This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.
What is the current status of trial NCT04438083?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-06-16. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT04438083?
The interventions under investigation include: CTX130 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04438083?
This trial is sponsored by CRISPR Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04438083's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI